

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 June 2024 (27.06.2024)



(10) International Publication Number
WO 2024/131837 A1

(51) International Patent Classification:
C12N 9/22 (2006.01)

(21) International Application Number:
PCT/CN2023/140228

(22) International Filing Date:
20 December 2023 (20.12.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2022/140354
20 December 2022 (20.12.2022) CN

(71) Applicant (for CN only): **WUXI BIOLOGICS (SHANGHAI) CO., LTD.** [CN/CN]; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(71) Applicant (for all designated States except CN): **WUXI BIOLOGICS IRELAND LIMITED** [IE/IE]; Mullagharlin, Dundalk, Co Louth, A91 X56F (IE).

(72) Inventors: **LIAO, Shanhui**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **QIU, Cunjia**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **CHEN, Xiaoyue**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **CAI, Jiexing**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **ZHOU, Weichang**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(74) Agent: **SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC**; 435 Guiping Road, Xuhui District, Shanghai 200233 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ENGINEERED NUCLEASE WITH HIGH SALT TOLERANCE

(57) Abstract: Provided is an engineered nuclease with high salt tolerance. The polypeptide comprises one or more mutations so that the polypeptide possesses more positive charged surface area in its three-dimensional structure. The polypeptide has at least 60% nuclease activity under a solution ionic strength more than 200 mM as compared to the nuclease having the sequence of SEQ ID NO: 1.

WO 2024/131837 A1